Fuente | Nº Citas | Fecha Actualización |
---|---|---|
scopus | 1509 | 29-10-2024 |
wos | 1354 | 29-10-2024 |
Año: 2016
Journal Impact Factor (JIF): 72.4060
Categoría | Edición | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|---|
MEDICINE, GENERAL & INTERNAL | SCIE | 1/155 | Q1 | T1 | D1 |
Año: 2017
Journal Citation Indicator (JCI): 23,770
Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
---|---|---|---|---|---|
MEDICINE, GENERAL & INTERNAL | 1/298 | Q1 | T1 | D1 | 99,83 |
Año:
2016
CiteScore:
61,100
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
General Medicine | 1/915 | Q1 | T1 | D1 |
SJR año:
2016
Factor de Impacto:
18,009
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Medicine (miscellaneous) | 3/2809 | Q1 | T1 | D1 |
Agencia | Código de Proyecto |
---|---|
Regeneron Pharmaceuticals | - |
Sanofi | - |
# | Autor | Afiliación |
---|---|---|
1 | Oregon Health & Science University (United States) | |
2 | Bieber, T. | Universität Bonn (Germany) |
3 | Guttman-Yassky, E. | Icahn School of Medicine at Mount Sinai (United States) |
4 | Beck, L. A. | University of Rochester Medical Center; Oregon Medical Research Center (United States) |
5 | Blauvelt, A. | Regeneron Pharmaceuticals (United States) |
6 | Cork, M. J. | The Sheffield Medical School (United Kingdom) |
7 | Silverberg, J. I. | Northwestern University Feinberg School of Medicine (United States) |
8 | Deleuran, M. | Aarhus Universitetshospital (Denmark) |
9 | Kataoka, Y. | Osaka Prefectural Medical Center for Respiratory and Allergic Diseases (Japan) |
10 | Lacour, J. P. | Centre Hospitalier Universitaire de Nice (France) |
11 | Kingo, K. | Tartu University Hospital (Estonia) |
12 | Worm, M. | Ludwig-Maximilians-Universität München; Charité – Universitätsmedizin Berlin (Germany) |
13 | Poulin, Y. | L'Hôtel-Dieu de Québec (Canada) |
14 | Wollenberg, A. | Ludwig-Maximilians-Universität München (Germany) |
15 | Soo, Y. | Regeneron Pharmaceuticals (United States) |
16 | Graham, N. M.H. | Regeneron Pharmaceuticals (United States) |
17 | Pirozzi, G. | Sanofi S.A. (France) |
18 | Akinlade, B. | Oregon Medical Research Center (United States) |
19 | Staudinger, H. | Sanofi S.A. (France) |
20 | Mastey, V. | Regeneron Pharmaceuticals (United States) |
21 | Eckert, L. | Sanofi S.A. (France) |
22 | Gadkari, A. | Regeneron Pharmaceuticals (United States) |
23 | Stahl, N. | Regeneron Pharmaceuticals (United States) |
24 | Yancopoulos, G. D. | Regeneron Pharmaceuticals (United States) |
25 | Ardeleanu, M. | Regeneron Pharmaceuticals (United States) |
# | Autoría grupal | Afiliación |
1 | Moreno Ramirez, David (SOLO 1 and SOLO 2 Investigators) | Sin datos () |